BeiGene is keeping its investment value close to the vest for now, Garvey said. BeiGene's initial outlay will cover land costs and construction for buildings "to house colleagues in a variety of disciplines," plus the manufacturing setup. RELATED: BeiGene's Brukinsa turns in 'near best case scenario' against Imbruvica in key CLL trial: analyst The site will be able to produce a "broad array of medicines" and will be built to support the company's current and future pipeline, though BeiGene is still hashing out the specifics, Garvey said.